- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01505998
Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions
January 6, 2012 updated by: Dr. Reddy's Laboratories Limited
An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fed Conditions
The purpose of this study single dose bioequivalence of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules with Lotrel® capsules in healthy human subjects and monitor clinical status, adverse events and laboratory investigations and assess relative safety and tolerance under fed conditions.
Study Overview
Detailed Description
An open-label randomized, single dose, two way crossover oral bioequivalence study to compare Amlodipine Besylate/Benazepril Hydrochloride 10 mg/40 mg capsules (Dr.
Reddy's Laboratories Ltd.,) with Lotrel® capsules Novartis Pharmaceuticals Corporation in healthy human subjects under fed conditions.
Study Type
Interventional
Enrollment (Actual)
49
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
A.P
-
Hyderabad, A.P, India, 500 051
- Vimta Labs Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects will provide written informed consent.
- Subjects must be healthy adults within 18-45 years of age (inclusive).
- Body mass index of ≥18 kg/m2 and ≤25 kg/m2, with body weight not less than 50 kg.
- Subjects must be of normal health as determined by medical history and physical examination performed within 15 days prior to the dosing of period I.
- Have normal ECG, Chest X-ray and vital signs.
- Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
- If subject is a female volunteer and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device(IUD), or abstinence.
or is postmenopausal for at least 1 year. or is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
•Each female subject will be given a urine pregnancy test at check-in for period-I, period-II and post study.
Exclusion Criteria:
- Subjects incapable of understanding the informed consent.
- Subjects with BP ≤90/60 mm/Hg or BP ≥140/90 mm/Hg
- History of hypersensitivity or idiosyncratic reaction to Amlodipine Besylate/Benazepril Hydrochloride or any other related drug.
- Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function. Subjects with a history of tuberculosis, epilepsy, asthma(during past 5 years),diabetes, psychosis or glaucoma will not be eligible for the study
- Regular smoker who smokes more than ten cigarettes daily and has difficulty in abstaining from smoking for the duration of each study period.
- Subjects who has taken over the counter or prescribed medications, including any enzyme modifying drugs or any systemic medication within the past 30 days prior to dosing in Period-I.
- History of any psychiatric illness, which may impair the ability to provide written, informed consent.
- Subjects who have a history of alcohol or substance abuse within the last 5 years
- Subjects with clinically significant abnormal values of laboratory parameters.
- Subjects who have participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months.
- Subjects who are unable to or likely to be non-compliant with protocol requirements or restrictions.
- Any subject in whom Amlodipine Besylate /Benazepril Hydrochloride is contraindicated for medical reasons
- Subjects who are intolerant to venipuncture
- Subjects with positive urine screen for drugs of abuse. All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each study period check-in. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate
- Female volunteers who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing
- Female volunteers demonstrating a positive pregnancy screen.
- All female subjects will be screened for pregnancy at check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study
- Female volunteers who are currently breast feeding.
- Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant during the study will not be allowed to participate. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Amlodipine Besylate/Benazepril HCl
Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
|
Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
Other Names:
|
Active Comparator: Lotrel
Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
|
Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence is based on Cmax and AUC parameters
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: I. S. Gandhi., MD, Vimta Labs Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
May 1, 2007
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
January 5, 2012
First Submitted That Met QC Criteria
January 6, 2012
First Posted (Estimate)
January 9, 2012
Study Record Updates
Last Update Posted (Estimate)
January 9, 2012
Last Update Submitted That Met QC Criteria
January 6, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Malnutrition
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Amlodipine
- Benazepril
Other Study ID Numbers
- 5531/06-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Umeå UniversityUniversity of California; Mead Johnson NutritionActive, not recruitingHealth of Formula-fed Children | Infant Infections in Formula-fed Children | Iron Status of Formula-fed ChildrenSweden
-
Dr. Reddy's Laboratories LimitedCompleted
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
Clinical Trials on Amlodipine Besylate/Benazepril HCl
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Novartis PharmaceuticalsCompleted
-
Mylan Pharmaceuticals IncCompleted
-
Mylan Pharmaceuticals IncCompleted
-
NovartisTerminatedHypertensionUnited States, Denmark, Finland, Norway, Sweden
-
NovartisCompletedHypertension | Left Ventricular HypertrophyUnited States
-
NovartisPfizerCompletedHypertensionUnited States
-
NovartisCompleted